BLU-667 is a highly specific RET inhibitor developed for the treatment of tumors with RET mutations and rearrangements, including NCOA4-RET and CCDC6-RET fusions, as observed in two of the analyzed pancreatic tumors. Here, NCOA4 is linked to pancreatic neoplasm.